When time is short and the odds are long, we're there – ensuring hard–to–treat patients have access to the most promising investigational therapies worldwide.
Early Access Care. The first name in second chances.
Leading the way in compassionate use
As the top specialist in managing early access programs for biopharma firms, we’re laser-focused on giving hope to patients with rare diseases and cancer.
To make it easier for these patients and their physicians to access treatment, we offer a level of service that is extraordinarily personalized.
Expertise for a complex world
Today, there’s a maze of country-specific regulations around investigational drugs. With 50+ years in drug development and 30+ in compassionate use, we can help you navigate it all.
Our many services for individuals and groups of patients include expanded access, compassionate use and post-trial access programs, as well as real-world data collection.
Inside our unique approach to early access
Yes, our business is about delivering medical breakthroughs. But first and foremost, it’s about helping people. In this video, see what sets us apart from other service providers.
Areas of focus
- Oncology
- Rare and ultra–rare diseases
- Serious and life–threatening conditions
A global program provider
Our specialists develop protocols and programs for firms in North America, South America, EMEA, Asia and Oceania.
Driven by a singular mission
We seek to give hard–to–treat patients what others take for granted. Another day. Another milestone. Another chance.